1 day ago · Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website highlighting data on mevrometostat data in ...

On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating.

Jan 24, 2025 · ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ORIC Pharmaceuticals in a report...

1 day ago · On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $13.39, after an incident involving a potential news leak.According to InvestingPro data, the company has shown remarkable momentum with a 20.69% return in the past week alone, reflecting strong market interest in this $918 million market cap biotech firm.

Feb 4, 2025 · On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ: ORIC), maintaining an Overweight stock rating. Trading at $11.49, ORIC has seen analyst targets...

1 day ago · Cantor Fitzgerald's stance is to buy ORIC shares ahead of the ASCO-GU presentation, and the firm is also organizing an investor dinner with ORIC management on February 13 in San Francisco. The ...

Jan 14, 2025 · Cantor Fitzgerald restated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC - Free Report) in a research note issued to investors on Tuesday, Benzinga reports. Several other equities analysts also recently issued reports on …

Feb 23, 2024 · ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of...

Feb 23, 2024 · On Friday, Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals (NASDAQ: ORIC), assigning an Overweight rating to the clinical-stage oncology-focused biotech company. The firm's...

On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...